bioMérieux – Third-Quarter 2017 Business Review

19 October, 2017

Marcy l'Étoile (France), October 19, 2017 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the six months ended September 30, 2017.

Sales

Consolidated sales came in at €1,674 million for the nine months ended September 30, 2017, up 10.8% as reported on the €1,512 million posted for the same period in 2016. The positive currency effects seen in the first six months of the year were almost entirely offset by the negative currency effects reported in the third quarter as the euro strengthened against a number of currencies, notably the U.S. dollar. At constant exchange rates and scope of consolidation, organic growth came to 10.7% year-on-year.

  • Solid growth in sales, up 10.7% at constant exchange rates and scope of consolidation
  • €1,674 million in sales
  • Up 10.8% as reported
  • microbiology, growth accelerated to nearly 8%
  • Contribution from all regions to the Group's strong sales dynamic, particularly the Asia-Pacific region, with sales in China and India up almost 15%

Alexandre Mérieux, Chief Executive Officer, said: "Third-quarter growth for bioMérieux once again reflected the strong sales dynamic we have enjoyed for several quarters. Robust growth for the microbiology lines and sustained growth for the molecular biology lines pushed sales up by more than 10% for the first nine months of the year, placing us firmly on track to achieving our annual targets."

About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2016, revenues reached €2,103 million, with 90% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market (Symbol: BIM/Reuters: BIOX.PA/Bloomberg: BIM.FP – ISIN: FR0010096479)

Corporate website: www.biomerieux.com
Investor website: www.biomerieux-finance.com

Contacts

Investor Relations

bioMérieux
Sylvain Morgeau
Tel.: +33 (0)4 78 87 22 37
investor.relations@biomerieux.com

Media Relations

bioMérieux
Aurore Sergeant
Tel.: +33 (0)4 78 87 20 53
media@biomerieux.com

Image Sept
Laurence Heilbronn
Tel.: +33 (0)1 53 70 74 64
lheilbronn@image7.fr

Claire Doligez
Tel.: +33 (0)1 53 70 74 48
cdoligez@image7.fr


Download the Full Press Release:

Download
Pioneering diagnostics